LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma

Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Arvind, Zhang, Jing, Rabbitts, Terence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314441/
https://www.ncbi.nlm.nih.gov/pubmed/30613826
_version_ 1783384101066113024
author Jain, Arvind
Zhang, Jing
Rabbitts, Terence
author_facet Jain, Arvind
Zhang, Jing
Rabbitts, Terence
author_sort Jain, Arvind
collection PubMed
description Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.
format Online
Article
Text
id pubmed-6314441
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-63144412019-01-02 LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma Jain, Arvind Zhang, Jing Rabbitts, Terence Clin Oncol (Belmont) Article Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option. 2017-01-05 /pmc/articles/PMC6314441/ /pubmed/30613826 Text en http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited http://creativecommons.org/licenses/by/4.0.
spellingShingle Article
Jain, Arvind
Zhang, Jing
Rabbitts, Terence
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
title LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
title_full LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
title_fullStr LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
title_full_unstemmed LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
title_short LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
title_sort lingo-1 is a new therapy target and biomarker for ewing sarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314441/
https://www.ncbi.nlm.nih.gov/pubmed/30613826
work_keys_str_mv AT jainarvind lingo1isanewtherapytargetandbiomarkerforewingsarcoma
AT zhangjing lingo1isanewtherapytargetandbiomarkerforewingsarcoma
AT rabbittsterence lingo1isanewtherapytargetandbiomarkerforewingsarcoma

Ejemplares similares